Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Winning the endgame against sleeping sickness: Efficacy profiling of acoziborole against African trypanosomes with the focus on Trypanosoma brucei rhodesiense. Local targets link to admitted publications; unresolved targets remain external evidence.
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness
10.1371/journal.pntd.0000923 · 2010 · External reference
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
10.1016/s2214-109x(21)00208-4 · 2021 · External reference
Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
10.3390/diseases10040090 · 2022 · External reference
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice
10.1016/s1473-3099(19)30612-7 · 2020 · External reference
New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine
10.1016/s1473-3099(24)00581-4 · 2025 · External reference
New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story
10.3390/tropicalmed5010029 · 2020 · External reference
Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies
10.1007/s40262-014-0136-3 · 2014 · External reference
Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis
10.1128/aac.00498-10 · 2010 · External reference
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis
10.1371/journal.pntd.0001151 · 2011 · External reference
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
10.1016/s1473-3099(22)00660-0 · 2023 · External reference
The STROGHAT study protocol: An intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole
10.12688/openreseurope.19077.1 · 2025 · External reference
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study
10.1007/s40262-023-01216-8 · 2023 · External reference
Epidemiology of human African trypanosomiasis
2014 · External reference
The impact of habitat fragmentation on tsetse abundance on the plateau of eastern Zambia
10.1016/j.prevetmed.2009.05.009 · 2009 · External reference
Evaluating the impact of declining tsetse fly (Glossina pallidipes) habitat in the Zambezi valley of Zimbabwe
10.1080/10106049.2019.1576780 · 2019 · External reference
The elimination of human African trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets
10.1371/journal.pntd.0012111 · 2024 · External reference
The phenomenon of treatment failures in Human African Trypanosomiasis
10.1046/j.1365-3156.2001.00775.x · 2001 · External reference
Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol
10.1046/j.1365-3156.1997.d01-122.x · 1997 · External reference
Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense
10.1128/aac.34.6.1183 · 1990 · External reference
Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part II. Parasitological and immunodiagnostic examination of the human population
1981 · External reference
Antigenic analysis in the Trypanosoma brucei group, using the agglutination reaction
10.1016/0035-9203(62)90088-3 · 1962 · External reference
Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense
10.1002/j.1460-2075.1985.tb03772.x · 1985 · External reference
Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers
10.2307/3282883 · 1989 · External reference
The Alamar Blue assay to determine drug sensitivity of African trypanosomes in vitro
10.1016/s0001-706x(97)00079-x · 1997 · External reference
Isothermal microcalorimetry - A quantitative method to monitor Trypanosoma congolense growth and growth inhibition by trypanocidal drugs in real time
10.1016/j.ijpddr.2018.03.003 · 2018 · External reference
In Vitro Drug Efficacy Testing Against Trypanosoma brucei
10.1007/978-1-0716-0294-2_46 · 2020 · External reference
Isothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparum
10.1371/journal.pntd.0001668 · 2012 · External reference
Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO)
1995 · External reference
Human African trypanosomiasis
10.1016/s0140-6736(09)60829-1 · 2010 · External reference
Human African trypanosomiasis
10.1016/s0140-6736(17)31510-6 · 2017 · External reference
Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis
10.1017/s003118201300098x · 2014 · External reference
Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans
2025 · External reference
